CONSIDeration
35 For the reasons put forward by the applicant in its submissions in support of the dispensation orders, I was and am satisfied that the Court should exercise its discretion to make the orders sought.
36 First, from the total number of affected policyholders identified in the searches, only 1,883 could not be identified. Of that number, an agent or broker address is available. The applicant intends to send the approved summary to all policyholders identified though its searches and, where a valid address of such affected policyholders cannot be obtained, to the addresses of the broker or agent who placed the business when it was originally underwritten.
37 Secondly, additional steps proposed by the applicant will assist in notifying affected policyholders of the proposed transfer. These include making available the proposed scheme, approved summary and actuarial report on the applicant's website and publishing the notice in a range of metropolitan newspapers as well as in New Zealand (the domicile of 21 identified policyholders).
38 Thirdly, the applicant draws attention to the fact that the actuarial evidence indicates that the implementation of the scheme will not have a materially adverse impact on the affected policyholders. AXIS commissioned Ernst & Young to provide an actuarial report on the proposed scheme. This report, dated 2 November 2016, was prepared by Mr Warrick Gard. AXIS also sought a peer review of Mr Gard's draft actuarial report by commissioning a report from Mr Rick Shaw of Deloitte Consulting Pty Ltd, dated 14 September 2016.
39 Actuarial evidence in support of the scheme as set out in the applicant's submissions is as follows:
(1) While AXIS's PCR coverage ratio at 31 December 2015 is 2.41, and following the proposed transfer the PCR coverage ratio for Swiss Re is estimated to be 1.38, this will not represent a material detriment to transferring policyholders. AXIS had deliberately targeted a relatively high PCR coverage ratio given that it was a new business with deteriorating claims experience.
(2) Swiss Re's target capital coverage ratio of 0.94 following the proposed transfer falls within Swiss Re's target capital coverage range of 0.90 to 1.10.
(3) Transferring policyholders will be comforted by the fact that Swiss Re is part of SRI, which has a higher credit rating than Axis Europe.
(4) No detriment will be experienced by Swiss Re's existing policyholders from a capital perspective as reinsurance arrangements will cede 100% of the liability to Swiss Re-Insurance Company Ltd.
(5) The increased credit risk to which Swiss Re is exposed is mitigated by the reinsurance arrangements placed with Swiss Re-Insurance Company Ltd.
(6) Swiss Re intends to adopt similar claims management to the applicant's current arrangements following the transfer.
(7) Mr Gard's review of the Q2 2016 solvency position and balance sheets of both the applicant and Swiss Re suggest that there has been no material change in the level of security afforded to policyholders of either entity compared to the position as at 31 December 2015.
40 The conclusion in the actuarial report of Ernst & Young at p 27 is that neither the change in the capital position or operations of Swiss Re as a result of the proposed transfer will materially adversely impact the existing or transferring policyholders. Mr Shaw concurs with the conclusion of Mr Gard (p 3 of the Deloitte report).
41 While the actuarial evidence is to be explained in more detail at the final hearing, the conclusions at this stage suggest a reduced likelihood of opposition to the scheme from transferring or existing policyholders at the final hearing.
42 Fourthly, Ms Neumueller appeared on behalf of APRA at the interlocutory hearing, noting that APRA considered the scheme documents and proposed some amendments that were incorporated in the amended interlocutory orders as handed up. Further, APRA recorded no objections to the interlocutory orders sought and will continue to be involved in overseeing preparations for the proposed transfer. As noted by Yates J in Gordian [2013] FCA 983 :
22. …the making of a dispensation order under s 17C(5) of the Act does not in any way fetter or restrict APRA's role in assessing and scrutinising every aspect of the schemes, nor does it limit in any way the exercise of the Court's discretion at a confirmation hearing. Any perceived deficiency in the notification of policyholders, even where it is done in accordance with dispensation orders, may be taken into account by the Court in determining whether to give its approval.
43 Fifthly, this scheme will also be subject to additional scrutiny by the High Court of Ireland.
44 These factors satisfy me that due to the nature of the scheme and the circumstances attending its preparation, it is not necessary for the applicant to comply with s 17C(2)(c).
45 It is for these reasons that I made the interlocutory orders sought by the applicant.
I certify that the preceding forty-five (45) numbered paragraphs are a true copy of the Reasons for Judgment herein of the Honourable Chief Justice Allsop.